Stock AQP AQUAPORIN A/S
Add to a list
To use this feature you must be a member
Log inSign up

Aquaporin A/S Share Price

Equities

AQP

DK0061555109

Water Utilities

Market Closed - Nasdaq Copenhagen
Other stock markets
 15:59:32 26/04/2024 BST 		5-day change 1st Jan Change
14.35 DKK -2.05% Intraday chart for Aquaporin A/S -4.01% -68.80%
04-05 Transcript : Aquaporin A/S, 2023 Earnings Call, Apr 05, 2024
04-05 Aquaporin A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * 100M 14.34M 1.15B Sales 2025 * 170M 24.38M 1.95B Capitalization 157M 22.53M 1.8B
Net income 2024 * -82M -11.76M -941M Net income 2025 * -52M -7.46M -597M EV / Sales 2024 * 2.77 x
Net Debt 2024 * 120M 17.21M 1.38B Net Debt 2025 * 171M 24.52M 1.96B EV / Sales 2025 * 1.93 x
P/E ratio 2024 *
-1.91 x
P/E ratio 2025 *
-3 x
Employees 82
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.49%
More Fundamentals * Assessed data

Chart Aquaporin A/S

Dynamic Chart

Latest news about Aquaporin A/S

Transcript : Aquaporin A/S, 2023 Earnings Call, Apr 05, 2024
Aquaporin A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Aquaporin A/S Provides Earnings Guidance for the Year 2024 CI
London Stocks Retreat Ahead of Final UK GDP Data for Q4 2023 MT
AstraZeneca Says Ultomiris Gets US FDA Approval to Treat Neuromyelitis Optica Spectrum Disorder MT
AstraZeneca Bags US FDA Clearance for Rare Autoimmune Disease Treatment Ultomiris MT
AstraZeneca Receives US Approval for Neuromyelitis Optica Spectrum Disorder Treatment MT
Aquaporin Announces Changes in Executive Management Team CI
Aquaporin A/S Provides Earnings Guidance for the Financial Year 2024 CI
Aquaporin A/S(CPSE:AQP) added to OMX Nordic Small Cap Index CI
Aquaporin A/S Maintains Earnings Guidance for the Full Year 2023 CI
AstraZeneca's Soliris Approved in China for Treatment of Neuromyelitis Optica Spectrum Disorder MT
AstraZeneca drug Solaris approved in China as NMOSD treatment AN
AstraZeneca's Rare Inflammatory Disease Drug for Adults Wins First-in-Class Nod in China MT
AstraZeneca working with FDA on Ultomiris risk evaluation changes AN
More news

Latest transcript on Aquaporin A/S

Logo Aquaporin A/S
Aquaporin A/S, 2023 Earnings Call, Apr 05, 2024
More transcripts

Press releases Aquaporin A/S

Major shareholder announcement AQ
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Aquaporin's shares AQ
Aquaporin raises DKK 172 million AQ
Notice convening the annual general meeting 2024 AQ
Aquaporin publishes prospectus and initiates rights issue AQ
More press releases

Quotes and Performance

1 day-2.05%
1 week-4.01%
Current month-55.57%
1 month-55.57%
3 months-59.58%
6 months-76.08%
Current year-68.80%
More quotes

Highs and lows

1 week
14.25
Extreme 14.25
15.00
1 month
14.25
Extreme 14.25
43.90
Current year
14.25
Extreme 14.25
47.90
1 year
14.25
Extreme 14.25
90.00
3 years
14.25
Extreme 14.25
173.00
5 years
14.25
Extreme 14.25
173.00
10 years
14.25
Extreme 14.25
173.00
More quotes

Managers and Directors - Aquaporin A/S

Managers TitleAgeSince
Matt Boczkowski CEO
 Chief Executive Officer 46 31/12/20
Peter Holme Jensen CEO
 Chief Executive Officer 54 31/12/04
Klaus Wulff DFI
 Director of Finance/CFO 51 19/05/22
Members of the board TitleAgeSince
Anne Broeng BRD
 Director/Board Member 62 31/03/18
Niels Thomas Heering CHM
 Chairman 69 31/12/14
Søren Bjørn Hansen BRD
 Director/Board Member 52 31/12/06
More insiders

Quotes

Date Price Change Volume
26/04/24 14.35 -2.05% 18,082
25/04/24 14.65 -1.35% 47,638
24/04/24 14.85 -1.00% 2,716
23/04/24 15 0.00% 4,178
22/04/24 15 +0.33% 23,178

Delayed Quote Nasdaq Copenhagen, April 26, 2024 at 03:59 pm

More quotes

Company Profile

Aquaporin A/S is a Denmark-based water tech company delivering technology built on nature’s own water filtration. Aquaporin revolutionizes water purification by merging biotechnological techniques and classical engineering. The Company’s aim is to commercialize biomimetic water membranes for households and industrial use in a variety of markets and applications. Aquaporin deploys direct sales, sales through distributors and commercial partnerships. Aquaporin operates through three segments; Drinking Water, Industrial Water, and Food & Beverage. The Company’s products include: Forward osmosis membranes, Drinking water membranes, ZERO - water purifier, ONE - water purifier, Brackish water RO membranes and Aquaporin Inside technology.
Sector
Water Utilities
More about the company

Income Statement Evolution

More financial data

Ratings for Aquaporin A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Water Supply & Irrigation Systems

1st Jan change Capi.
AQUAPORIN A/S Stock Aquaporin A/S
-68.80% 22.49M
AMERICAN WATER WORKS COMPANY, INC. Stock American Water Works Company, Inc.
-8.49% 23.53B
GUANGDONG INVESTMENT LIMITED Stock Guangdong Investment Limited
-32.75% 3.19B
BEIJING ENTERPRISES WATER GROUP LIMITED Stock Beijing Enterprises Water Group Limited
+13.79% 2.54B
COMPANHIA CATARINENSE DE ÁGUAS E SANEAMENTO - CASAN Stock Companhia Catarinense de Águas e Saneamento - CASAN
-.--% 2.12B
SJW GROUP Stock SJW Group
-18.13% 1.72B
COMPANHIA DE SANEAMENTO DE MINAS GERAIS Stock Companhia de Saneamento de Minas Gerais
+5.32% 1.6B
COMPANHIA DE SANEAMENTO DO PARANÁ - SANEPAR Stock Companhia de Saneamento do Paraná - SANEPAR
-10.87% 1.52B
MANILA WATER COMPANY, INC. Stock Manila Water Company, Inc.
+30.91% 1.24B
GUANGDONG SHUNKONG DEVELOPMENT CO.,LTD. Stock Guangdong Shunkong Development Co.,Ltd.
-11.02% 1.15B
Water Supply & Irrigation Systems
  1. Stock Market
  2. Equities
  3. AQP Stock